WBA Stock Surges 0.50% in Pre-Market Trading on Apr 22, 2026

Walgreens Boots Alliance, Inc. (WBA) gained 0.50% in pre-market trading on April 22, 2026, climbing to $11.98 USD on the NASDAQ. The pharmacy-led retailer showed modest upward momentum despite ongoing operational challenges. WBA stock has climbed 30.36% year-to-date but remains under pressure from negative earnings and weak profitability metrics. With a market cap of $10.37 billion, the company operates over 13,000 retail locations globally. Investors are watching WBA stock closely as the company navigates a challenging healthcare retail landscape.

WBA Stock Price Action and Trading Volume

WBA stock opened at $11.98 in pre-market trading, up $0.06 or 0.50% from the previous close of $11.92. The stock is trading within its daily range of $11.98, showing limited intraday movement so far. Volume surged to 452.08 million shares, representing 26.69x the average daily volume of 16.94 million shares. This exceptional trading activity signals strong investor interest in WBA stock during the pre-market session.

The 52-week range shows WBA stock trading between $8.08 and $13.25, placing the current price near mid-range levels. Year-to-date performance remains positive at +30.36%, though the stock has declined 63.06% over the past three years. The 50-day moving average sits at $11.66, while the 200-day moving average stands at $10.81, indicating WBA stock is trading above both key technical levels.

Financial Metrics and Profitability Concerns

WBA stock faces significant profitability headwinds. The company reported a negative EPS of -$7.29, resulting in a negative PE ratio of -1.64. Net income per share came in at -$3.81, reflecting ongoing losses. The net profit margin stands at -2.81%, indicating the company is losing money on each dollar of revenue generated. Operating cash flow per share is minimal at $0.28, while free cash flow per share is deeply negative at -$0.59.

Key balance sheet metrics reveal structural challenges. The debt-to-equity ratio is elevated at 4.04x, while the current ratio of 0.60 suggests liquidity concerns. Return on equity is negative at -38.81%, and return on assets is -4.74%. However, the price-to-sales ratio of 0.09 suggests WBA stock may be undervalued relative to revenue generation. The company maintains a dividend yield of 2.09% with a quarterly dividend of $0.25 per share.

Market Sentiment and Trading Activity

Trading Activity: The exceptional volume of 452.08 million shares in pre-market trading dwarfs the average daily volume, indicating heightened investor attention. This 26.69x relative volume spike suggests significant institutional or retail positioning ahead of the regular market session. The modest 0.50% gain despite heavy volume indicates balanced buying and selling pressure.

Liquidation Concerns: WBA stock’s negative free cash flow of -$0.59 per share raises questions about the company’s ability to fund operations and shareholder returns. The working capital deficit of -$10.26 billion signals potential liquidity stress. However, the company maintains a dividend, suggesting management confidence in near-term cash generation. Analysts remain cautious, with one sell rating and a consensus recommendation of 2.00 (Sell).

Analyst Ratings and Company Grade

Meyka AI rates WBA stock with a grade of C+, reflecting mixed fundamentals and operational challenges. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating recommendation is HOLD, suggesting investors should maintain current positions but avoid new accumulation.

Analyst consensus shows one sell rating with no buy or hold recommendations tracked. The DCF valuation model suggests Strong Buy potential, but this conflicts with weak profitability metrics. ROE and ROA scores are critically low at 1, indicating poor returns on shareholder capital and assets. The PE score of 1 reflects the negative earnings situation. The price-to-book ratio score of 4 suggests the stock may offer value at current levels. Track WBA on Meyka for real-time updates and grade changes.

Revenue Growth and Operational Performance

WBA stock’s parent company reported revenue growth of 6.17% year-over-year, demonstrating the core business remains resilient. However, gross profit declined 2.02%, indicating margin compression from rising costs. Operating income fell 104.53%, turning positive operations into losses. Net income plummeted 180.39%, reflecting significant profitability deterioration.

Longer-term trends are concerning. Five-year net income growth per share is -331.55%, while three-year growth is -440.40%. Operating cash flow has declined 80.57% over five years. Dividend per share growth is negative at -24.04% annually, though the company maintains its payout. The company’s inability to convert revenue growth into profit growth remains the core investment challenge for WBA stock.

Valuation and Investment Outlook

WBA stock trades at a price-to-sales ratio of 0.09, among the lowest in the healthcare sector, suggesting potential undervaluation. The enterprise value-to-sales ratio of 0.33 also appears attractive. However, negative earnings make traditional valuation metrics unreliable. The price-to-book ratio of 1.44 indicates the stock trades slightly above book value despite negative returns on equity.

The earnings announcement is scheduled for June 25, 2025, providing a catalyst for potential volatility. Investors should monitor whether management can stabilize operations and return to profitability. The combination of heavy pre-market volume, modest price gains, and weak fundamentals suggests cautious sentiment. WBA stock remains a turnaround story requiring operational improvements before attracting significant institutional capital.

Final Thoughts

WBA stock gained 0.50% to $11.98 in pre-market trading on April 22, 2026, driven by exceptional volume of 452.08 million shares. While the year-to-date performance of +30.36% shows recovery, fundamental challenges persist. Negative earnings of -$7.29 per share, weak profitability margins, and elevated debt levels remain serious concerns. The Meyka AI grade of C+ with a HOLD recommendation reflects this mixed picture. The company’s 2.09% dividend yield provides some income support, but sustainability depends on improved cash generation. Investors should await the June earnings report for clarity on turnaround progress. These grades are not guaranteed and we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.